Spadin
Overview
Spadin is a 17-amino acid peptide derived from the propeptide released during maturation of sortilin, a neurotensin receptor. It functions as an antagonist of the TREK-1 potassium channel, which is implicated in the pathophysiology of major depressive disorder.
Mechanism of Action
By blocking TREK-1, spadin increases neuronal excitability and promotes hippocampal neurogenesis, providing a novel antidepressant mechanism distinct from monoaminergic pathways.
Research Summary & Key Findings
Preclinical rodent studies have demonstrated rapid antidepressant effects within 4 days of administration, with efficacy comparable to classical antidepressants but with faster onset. Published findings in translational psychiatry journals have shown TREK-1 blockade correlates with increased BDNF expression and synaptic plasticity markers. No clinical trial data in humans have been published to date.
Clinical Status
Spadin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed — "Spadin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Spadin"
Registered interventional and observational studies, including status and phase.
- PubChem — "Spadin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cognitive
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotecti...
View detailsSelank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stabi...
View detailsCerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that m...
View detailsP21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neuro...
View detailsStart Your Consultation
Get an AI-proposed Spadin protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Spadin.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.